8-K: INNOVATE Corp. Reports Mixed Q4 and Full Year 2023 Results Amidst Strategic Shifts

INNOVATE Corp. announced its fourth quarter and full year 2023 results, showing a revenue decrease but highlighting progress in key strategic areas.

Summary

• INNOVATE Corp. reported a consolidated revenue of $361.0 million for the fourth quarter of 2023, a decrease of 11.8% compared to the same period in 2022.
• The full year revenue for 2023 was $1,423.0 million, down 13.1% from $1,637.3 million in 2022.
• The company's net loss attributable to common stockholders for Q4 2023 was $9.6 million, compared to a net loss of $7.0 million in Q4 2022.
• For the full year, the net loss attributable to common stockholders was $37.6 million, an improvement from the $40.8 million loss in the previous year.
• Total Adjusted EBITDA for the fourth quarter was $21.5 million, a decrease from $28.1 million in the prior year quarter.
• The full year Adjusted EBITDA was $65.0 million, down from $68.1 million in 2022.
• The Infrastructure segment, DBM Global, reported Q4 revenue of $353.8 million, a 10.9% decrease year-over-year, but grew gross margin to 16.4%.
• DBM Global's backlog was reported at $1.1 billion, with an adjusted backlog of $1.2 billion as of December 31, 2023, down from $1.8 billion the previous year.
• The Life Sciences segment saw R2 Technologies achieve record growth in North America for system sales and patients treated.
• The Spectrum segment experienced a revenue decrease due to the termination of the Azteca America network, but is exploring new commercial opportunities with ATSC 3.0 and 5G broadcasting.

Sentiment

Score: 4

Explanation: The document presents mixed results with some positive developments in specific segments, but overall financial performance is down and there are concerns about the company's listing status and debt. The sentiment is cautiously negative.

Positives

• DBM Global demonstrated strong margin expansion, with a 200 basis point increase in gross margin year-over-year.
• R2 Technologies achieved record growth in North America, indicating strong market demand for its products.
• The Life Sciences segment is making progress with regulatory approvals and market expansion.
• The Spectrum segment is actively pursuing new revenue streams through ATSC 3.0 and 5G broadcasting opportunities.
• The company's cash position remained relatively stable year-over-year.

Negatives

• Consolidated revenue decreased by 11.8% in Q4 2023 and 13.1% for the full year, primarily driven by the Infrastructure segment.
• The company reported a net loss of $9.6 million in Q4 2023, an increase from the $7.0 million loss in the same period of 2022.
• Adjusted EBITDA decreased by $6.6 million in Q4 2023 compared to the prior year quarter.
• DBM Global's backlog decreased from $1.8 billion to $1.2 billion year-over-year.
• The Spectrum segment experienced a revenue decrease due to the termination of the Azteca America network.
• The company received a notice from the NYSE regarding non-compliance with the minimum average closing price requirement.

Risks

• The company's substantial indebtedness and dependence on distributions from subsidiaries pose financial risks.
• The company is dependent on key personnel, and their loss could negatively impact operations.
• Volatility in the trading price of the company's common stock is a concern.
• Supply chain disruptions, labor shortages, and increased price levels could impact the company's performance.
• Uncertain global economic conditions and increased competition in the markets could affect the company's business.
• The company's ability to raise additional capital or refinance existing debt on attractive terms is uncertain.
• The company faces the risk of not regaining compliance with the NYSE's continued listing standards.

Future Outlook

The company plans to convert backlog to revenue and pursue market opportunities in 2024, with a focus on strategic initiatives across its operating segments. They are also working to regain compliance with the NYSE listing standards.

Management Comments

• Avie Glazer, Chairman of INNOVATE, stated that 2023 was another successful year with exciting developments across the three operating segments.
• Paul Voigt, INNOVATE's interim CEO, expressed pleasure with the 2023 results, highlighting DBM's strong performance and margin expansion, as well as progress at MediBeacon and R2.

Industry Context

The results reflect a mixed performance in a challenging market environment, with the Infrastructure segment facing headwinds due to project timing and size, while the Life Sciences segment shows strong growth potential. The Spectrum segment is adapting to changes in the broadcasting landscape by exploring new technologies and partnerships. The company is navigating a complex environment with both challenges and opportunities.

Comparison to Industry Standards

• DBM Global's gross margin expansion to 16.4% is a positive sign, but its revenue decline of 10.9% year-over-year indicates challenges in the construction sector, which is facing headwinds from tightening credit markets. Comparible companies such as Tutor Perini Corporation (TPC) and Granite Construction Incorporated (GVA) have also reported mixed results in recent quarters, with some experiencing similar revenue declines due to project delays and market conditions.
• R2 Technologies' growth in North America is impressive, with a 76% sequential growth and 111% full year-over-year growth in system sales. This performance is strong compared to other medical device companies in the aesthetic market, such as Cutera (CUTR) and InMode (INMD), which have also reported growth but not at the same rate.
• The Spectrum segment's revenue decline due to the termination of Azteca is a significant setback, but the company's efforts to explore new opportunities with ATSC 3.0 and 5G broadcasting are in line with industry trends. Companies like Sinclair Broadcast Group (SBGI) and Nexstar Media Group (NXST) are also exploring similar technologies, but the success of these initiatives is still uncertain.
• The overall financial performance of INNOVATE Corp. is mixed, with a decrease in revenue and Adjusted EBITDA, but the company is making progress in key strategic areas. The company's performance is below the average of its peers in terms of revenue growth, but its margin expansion in the Infrastructure segment and growth in the Life Sciences segment are positive signs.

Stakeholder Impact

• Shareholders are impacted by the decrease in revenue and net loss, as well as the notice from the NYSE regarding non-compliance with the minimum average closing price requirement.
• Employees may be affected by cost reduction initiatives and potential restructuring.
• Customers of DBM Global may experience changes in project timelines due to market conditions.
• Customers of R2 Technologies are benefiting from the company's growth and product expansion.
• Suppliers may be impacted by changes in the company's financial performance and strategic shifts.
• Creditors are exposed to risks associated with the company's substantial indebtedness.

Next Steps

• The company plans to convert backlog to revenue and pursue market opportunities in 2024.
• The company intends to regain compliance with the NYSE's continued listing standards.
• MediBeacon will continue to work through the FDA approval process.
• The Spectrum segment will continue to explore opportunities related to 5G broadcast TV.

Key Dates

Keywords

INNOVATE Corp, DBM Global, R2 Technologies, MediBeacon, HC2 Broadcasting, Adjusted EBITDA, Revenue, Net Loss, Backlog, ATSC 3.0, 5G Broadcasting, NYSE Listing, Life Sciences, Infrastructure, Spectrum